Differential analysis of adverse reactions between primary and recurrent gliomas treated with apatinib
Objective To investigate whether there are differences in the various complications of apatinib in the treatment of primary and recurrent gliomas,as well as its dose correlation.Methods This study concluded 103 patients with glioma who received apatinib treatment at the First Affiliated Hospital of Zhengzhou University from August 2016 to September 2019 and a retrospective analysis was conducted.The complications were analyzed.T-test and logistic regression were used to explore independent related factors.Results Among 103 patients who received apatinib,a total of 44 cases experienced different types of ad-verse reactions,mainly including elevated blood pressure 16 cases(15.53％),hand foot syndrome 11 ca-ses(10.68％),gastrointestinal reactions 10 cases(9.71％),etc.The frequency of these adverse reac-tions in recurrent gliomas[47.19％(42/89)]was significantly higher than that in primary gliomas[14.29％(2/14),P＜0.05].The occurrence and category of adverse reactions to apatinib were not sig-nificantly correlated with the dosage taken(P＞0.05).Conclusion There were significant differences in the adverse reactions of apatinib in the treatment of primary and recurrent gliomas,but no dose correlation was found.
NETL
NSTL
万方数据
